PHILADELPHIA--(BUSINESS WIRE)--VintaBio, a biotech manufacturer specializing in high-yield, high-purity viral vectors for gene therapy, today presented data further demonstrating the advantages and ...

A mathematical model could help reduce the experimental effort needed to develop production processes for gene therapies. The digital twin, developed by a team at University College London (UCL) in ...

Vaccines are arguably one of the most important medical innovations in human history. When it comes to which diseases have successfully been targeted with vaccines, however, the playing field is far ...

Viral vectors dominate gene therapy, with lentivirus, adenovirus, and AAV being key players, each with unique advantages and limitations. Non-viral vectors, such as lipid nanoparticles and GalNAc, ...

Gene and cell therapy is moving fast – and in a clear direction. Programs are pushing toward more complex payloads, virus-free engineering, and manufacturing models that can scale from early research ...

Transfection techniques are pivotal advances in molecular biology that allow scientists to reliably introduce DNA, RNA, ribonucleoproteins (RNPs), and other molecules into cells. Several delivery ...

Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...

Polymer-based gene delivery systems represent a promising class of non-viral vectors, offering significant advantages in safety, structural versatility, biodegradability, and the potential for ...